RPGLF (Regent Pacific Group) Debt-to-Equity: -0.59 (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

RPGLF Regent Pacific Group Ltd RPGLF
13 GF Score
Price $0.01
! 7 Warning Signs
View Full Analysis

What is Regent Pacific Group Debt-to-Equity?

Regent Pacific Group RPGLF 13 Debt-to-Equity is -0.59 as of Dec. 2025. GuruFocus rates RPGLF with a GF Score™ of 13/100. The stock has 7 warning signs investors should review. Among 812 Drug Manufacturers companies, Regent Pacific Group ranks worse than 123152.59% on this metric.

Regent Pacific Group's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2025 was $3.93 Mil. Regent Pacific Group's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2025 was $0.01 Mil. Regent Pacific Group's Total Stockholders Equity for the quarter that ended in Dec. 2025 was $-6.64 Mil. Regent Pacific Group's debt to equity for the quarter that ended in Dec. 2025 was -0.59.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Regent Pacific Group's Debt-to-Equity or its related term are showing as below:

RPGLF' s Debt-to-Equity Range Over the Past 10 Years
Min: -0.77   Med: 0.13   Max: 5.29
Current: -0.59

During the past 13 years, the highest Debt-to-Equity Ratio of Regent Pacific Group was 5.29. The lowest was -0.77. And the median was 0.13.

RPGLF's Debt-to-Equity is not ranked
in the Drug Manufacturers industry.
Industry Median: 0.27 vs RPGLF: -0.59

Regent Pacific Group  (OTCPK:RPGLF) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Regent Pacific Group Debt-to-Equity Related Terms

Regent Pacific Group Debt-to-Equity Historical Data

* Premium members only.

The historical data trend for Regent Pacific Group's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Regent Pacific Group Debt-to-Equity Chart

Regent Pacific Group Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Debt-to-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.36 5.29 -0.77 -0.57 -0.59

Regent Pacific Group Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.77 -0.42 -0.57 -0.42 -0.59

RPGLF vs ZTS, UTHR: Debt-to-Equity Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Regent Pacific Group's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Regent Pacific Group Debt-to-Equity vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Regent Pacific Group's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Regent Pacific Group's Debt-to-Equity falls into.


RPGLF
13GF Score
Regent Pacific Group Ltd RPGLF
Debt-to-Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Regent Pacific Group Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Regent Pacific Group's Debt to Equity Ratio for the fiscal year that ended in Dec. 2025 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(3.927 + 0.012) / -6.641
=-0.59

Regent Pacific Group's Debt to Equity Ratio for the quarter that ended in Dec. 2025 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(3.927 + 0.012) / -6.641
=-0.59

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Debt-to-Equity →
What does a Debt-to-Equity of -0.59 mean?
Regent Pacific Group (RPGLF) has a Debt-to-Equity of -0.59 as of Dec. 2025. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Regent Pacific Group and its competitors. According to the industry distribution chart, Regent Pacific Group ranks #999999 out of 812 companies in the Drug Manufacturers industry.
Is Regent Pacific Group's Debt-to-Equity too high?
Regent Pacific Group's current Debt-to-Equity is -0.59. Based on the distribution chart, Regent Pacific Group ranks #999999 out of 812 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Regent Pacific Group has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.
How does Regent Pacific Group's Debt-to-Equity compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Regent Pacific Group ranks #999999 out of 812 companies for Debt-to-Equity. This places Regent Pacific Group in the lower half of its industry. The industry median Debt-to-Equity is 0.27. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Drug Manufacturers company?
The median Debt-to-Equity among Drug Manufacturers companies is 0.27, based on 812 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Regent Pacific Group and its competitors. For the Drug Manufacturers industry, the median Debt-to-Equity is 0.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Regent Pacific Group's current Debt-to-Equity is -0.59. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Regent Pacific Group stock overvalued right now?
Regent Pacific Group (RPGLF) has a current Debt-to-Equity of -0.59. The current Debt-to-Equity is -0.59. Regent Pacific Group's overall GF Score™ is 13/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Regent Pacific Group (RPGLF), the current Debt-to-Equity is -0.59 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Regent Pacific Group Business Description

Other Exchanges 00575:Hong KongRPG:Germany
Address 5 Queen\'s Road Central, 8th Floor, Henley Building, Hong Kong, HKG
Regent Pacific Group Ltd is an investment holding company that runs through two segments: Biopharma and Corporate Investment. Its Biopharma segment is engaged in the research, development, manufacturing, marketing, and sales of pharmaceutical products, and it also develops artificial intelligence (AI) systems for the field of biological aging clocks. The Corporate Investment segment is engaged in the investment in listed and unlisted corporate entities. The majority of its revenue comes from the Biopharma segment. Geographically, the Europe; U.S.; and Asia Pacific. It derives maximum revenue from Europe.
13GF Score

Get the complete analysis for RPGLF

Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.01
Price